Methodological Issues in Taquet et al.‘s analysis preclude any conclusions regarding AS01 adjuvant’s specific role in dementia prevention
Taquet et al. evaluated the impact of AS01-adjuvanted vaccines on subsequent dementia diagnosis<sup>1</sup>. The authors conclude: "No difference was observed between the two AS01-adjuvanted vaccines, suggesting that the AS01 adjuvant itself plays a direct role in lowering dementia risk". Although the study offers promising evidence, the inference regarding the role of AS01 adjuvant in dementia prevention is not convincingly supported by the presented data or other published literature<sup>2</sup>.
Authors
- Kate Luisi (ORCID: https://orcid.org/0000-0003-2945-8712)
- Caihua Liang (ORCID: https://orcid.org/0009-0004-8375-631X)
- Alejandro Cané (ORCID: https://orcid.org/0000-0003-0778-6862)
- Elizabeth Begier (ORCID: https://orcid.org/0000-0002-1287-5416)
- S. Williams (ORCID: https://orcid.org/0000-0001-5867-8162)
Institutions
- Pfizer (United States) (US)
- Pfizer (Ireland) (IE)
Publication Details
- Journal
- npj Vaccines
- Published
- 2025-12-05
- DOI
- https://doi.org/10.1038/s41541-025-01309-4
- Citations
- 1
- Primary Topic
- Immune responses and vaccinations
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- Pfizer